These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 354976)

  • 1. Clinical aspects of dopamine agonists and antagonists.
    Bianchine JR; Shaw GM; Greenwald JE; Dandalides SM
    Fed Proc; 1978 Aug; 37(10):2434-9. PubMed ID: 354976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine: pharmacologic and therapeutic aspects.
    Velasco M; Luchsinger A
    Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    Costentin J
    Encephale; 1979; 5(2):121-49. PubMed ID: 38958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Fed Proc; 1978 Jun; 37(8):2181-91. PubMed ID: 350633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuous and intermittent levodopa differentially affect basal ganglia function.
    Juncos JL; Engber TM; Raisman R; Susel Z; Thibaut F; Ploska A; Agid Y; Chase TN
    Ann Neurol; 1989 May; 25(5):473-8. PubMed ID: 2774488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuropharmacology of apomorphine (review of the literature)].
    Zharkovskiĭ AM; Allikmets LKh
    Farmakol Toksikol; 1981; 44(2):226-32. PubMed ID: 7023969
    [No Abstract]   [Full Text] [Related]  

  • 8. Activity of ibopamine on central nervous system in mice and rats.
    Ferrini R; Miragoli G; Sala R; Reggiani A
    Arzneimittelforschung; 1986 Feb; 36(2A):327-30. PubMed ID: 3707643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG; Diederich NJ
    Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the clinical pharmacology of Parkinson's disease.
    Montastruc JL
    Therapie; 1991; 46(4):293-303. PubMed ID: 1683024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, dopaminergic profile, and molecular dynamics calculations of N-aralkyl substituted 2-aminoindans.
    Andujar SA; de Angel BM; Charris JE; Israel A; Suárez-Roca H; López SE; Garrido MR; Cabrera EV; Visbal G; Rosales C; Suvire FD; Enriz RD; Angel-Guío JE
    Bioorg Med Chem; 2008 Mar; 16(6):3233-44. PubMed ID: 18166467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of dopamine agonists in Parkinson's disease management.
    Montastruc JL; Rascol O; Senard JM
    Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
    Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
    Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of mesocortical dopamine neurons.
    Bannon MJ; Roth RH
    Pharmacol Rev; 1983 Mar; 35(1):53-68. PubMed ID: 6138783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action of dopamine receptor agonists in forebrain and hypothalamus: rotational behavior, ovulation, and dopamine turnover.
    Fuxe K; Agnati LF; Corrodi H; Everitt BJ; Hökfelt T; Löfström A; Ungerstedt U
    Adv Neurol; 1975; 9():223-42. PubMed ID: 1146654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.